ABSORPTION OF APOMORPHINE BY VARIOUS ROUTES IN PARKINSONISM

被引：76

作者：

GANCHER, ST ^{[1
]}

NUTT, JG ^{[1
]}

WOODWARD, WR ^{[1
]}

机构：

[1] OREGON HLTH SCI UNIV,SCH MED,DEPT NEUROL,PORTLAND,OR 97201

来源：

MOVEMENT DISORDERS | 1991年 / 6卷 / 03期

关键词：

APOMORPHINE; SUBLINGUAL; PARKINSONISM; BIOAVAILABILITY;

D O I：

10.1002/mds.870060304

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

We wanted to determine the absorption and clinical effect of sublingual (SL) and transdermal apomorphine in parkinsonism. Patients received single SL apomorphine doses (N = 7) and the absorption was compared with parenteral (N = 5) and oral (N = 4) doses. One patient received a transdermal dose of apomorphine. The relative bioavailability of SL apomorphine ranged from 10 to 22% of a parenteral apomorphine dose. Oral apomorphine was less than 4% bioavailable, and the transdermal dose did not produce detectable plasma levels. Three patients with motor fluctuations responded to SL apomorphine, with a latency to effect of 20-40 min and a duration of effect of 15-100 min. One patient used SL apomorphine as an adjunct with levodopa, and during 1 month reported a large decrease in "off" periods. We conclude that apomorphine is effectively absorbed by the sublingual route.

引用

页码：212 / 216

页数：5

共 17 条

[1]

Obeso JA, Grandas F, Vaamonde J, Luquin MR, Martinez-Lage JM., Apomorphine infusion for motor fluctuations in Parkinson's disease, Lancet, 1, pp. 1376-1377, (1987)

[2]

Stibe C, Lees A, Stern G., Subcutaneous infusion of apomorphine and lisuride in the treatment of parkisonian on‐off fluctuations, Lancet, 1, (1987)

[3]

Stibe CM, Kempster PA, Lees AJ, Stern GM., Subcutaneous apomorphine in parkinsonian on‐off oscillations, Lancet, 1, pp. 403-406, (1988)

[4]

Pollak P, Champay AS, Hommel M, Perret JE, Benabid AL., Subctaneous apomorphine in Parkinson's disease, J Neurol Neurosurg Psychiatry, 52, (1989)

[5]

Poewe W, Kleedorfer B, Gerstenbrand F, Oerterl W., Subcutaneous apomorphine in Parkinson's disease, Lancet, 1, (1988)

[6]

Corsini GU, Gessa GL, Del Zompo M, Mangoni A., Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease, Lancet, 1, pp. 954-956, (1979)

[7]

Gancher ST, Woodward WR, Boucher B, Nutt JG., Peripheral pharmacokinetics of apomorphine in humans, Ann Neurol, 26, pp. 232-238, (1989)

[8]

DiChiara G, Gessa GL., Pharmacology and neurochemistry of apomorphine, Adv Pharmacol Chemotherapeutics, 15, pp. 87-159, (1978)

[9]

Colpaert FC, Van Bever WFM, Leysen JEM., Apomorphine: chemistry, pharmacology, biochemistry, Int Rev Neurobiol, 19, pp. 225-268, (1976)

[10]

Nutt JG, Woodward WR, Hammerstad JP, Carter J, Anderson JL., “On‐off” phenomenon in Parkinson's disease: relationship to L‐dopa absorption and transport, N Engl J Med, 310, pp. 483-488, (1984)

← 1 2 →